Perspectives and Opportunities for Nanomedicine in the Management of Atherosclerosis

Size: px
Start display at page:

Download "Perspectives and Opportunities for Nanomedicine in the Management of Atherosclerosis"

Transcription

1 Perspectives and Opportunities for Nanomedicine in the Management of Atherosclerosis Zahi A. Fayad, PhD, FAHA, FACC Professor of Radiology and Medicine (Cardiology) Director, Translational and Molecular Imaging Institute Mount Sinai School of Medicine, New York, NY August 26, ESC, Munich

2 Disclosures Funding American Heart Association fellowship (DPC) K99 EB (DPC) NHLBI R21 HL (KSB) NIH/NCRR S10RR02656 & S10RR (CYT) NIH R01 HL071021, HL and EB009638; NIH/NCRR UL1RR029887; NHLBI HHSN C (ZAF)

3

4

5

6 Cardiovascular nanotechnology: the opportunity Combine power of innovation in nano-materials and CV biology to develop new solutions in cardiovascular disease Detect disease before health has deteriorated - Sensors - Imaging Deliver therapeutics - Local delivery - Improved efficacy - Post-therapy monitoring Develop research tools to enhance understanding of the disease

7 Cardiovascular nanotechnology: the opportunity Tang J et al. Curr. Cardiovasc. Imaging Reports 2011 Lobatto M et al. Nature Reviews Drug Discovery 2011

8 Molecular imaging in atherosclerosis Leuschner & Nahrendorf, Circ Res 2011 Buxton DB et al. Circ 2011; 123:

9 Osborn EA & Jaffer F JACC Imaging 2012

10 Molecular Imaging in vivo characterization and measurement of biologic processes at the cellular and molecular level [via imaging] - Weissleder and Mahmood, 2001, Radiology targeting group contrast generating substance

11 Cardiovascular nanotechnology: the opportunity Lipid-based nanoparticles Allows a modular approach to particle assembly Straightforward synthesis WJM Mulder et al, Acc. Chem. Res., 2009, 42, 7,

12 Biodistribution <5.5 nm cleared by kidneys >100 nm taken up by Kupffer cells Nel AE et al. Nat Mat 2009

13 Lobatto et al. Nat Rev Drug Discov Nanoparticle targeting in atherosclerosis

14 Why use lipoproteins as contrast agents? Lipoproteins have important biological functions in the body Lipoproteins are heavily involved in atherosclerosis Lipoprotein receptors are often overexpressed in tumors Involvement in other diseases, such as hypercholesterolemia Natural (non-immunogenic) and biodegradable

15

16 HDL: a contrast/drug delivery platform MRI contrast agent Fluorescence CT contrast agent Targeted drug delivery

17 HDL: a contrast/drug delivery platform MRI contrast agent Fluorescence CT contrast agent Targeted drug delivery

18 Nanoparticle Drug Delivery Enhanced circulation half-life Protection from inactivation and interactions with plasma constituents Minimizing systemic exposure of the drug Favourable biodistribution profiles Local accumulation and retention Decreasing dose, altering mode of action and minimizing adverse effects -> Improved efficacy

19 Kamaly N et al. Chem Soc Rev 2012 Timeline of Clinical Stage Nanomedicine Firsts in Oncology

20 Potential and Challenges Buxton DB et al. Circ 2011; 123:

21

22 Large-Scale Production of HDL Nanoparticles

23 Microfluids produced HDL-NPs Macrophage Subclasses Uptake

24 High Risk Patients: New Treatment Paradigm Acute IV-Rx Routine Rx Rapid plaque stabilization/regression Short term risk reduction Routine Rx Complement routine Rx: PCI risk factors reduction, such as statins, antiplatelet and blood pressure Rx Long term plaque stabilization/regression Long term risk reduction Modified from PK Shah Future Lipidol 2006

25 Corticosteroids: Effect on Atherosclerosis Corticosteroids exhibit an anti-inflammatory pharmacological effect Prevent plaque formation and restenosis in preclinical models Poon et al. Atherosclerosis 2001 Ribichini et al. JACC 2007 Willem J.M. Mulder However: Not clinically suitable because: High and frequent dosing required Non specific, low efficacy, adverse effects

26 Liposomal glucocorticoids Liposomal glucocorticoids Enhanced circulation half-life Protection from inactivation and interactions with plasma constituents

27 Nanoparticle (NP)-glucocorticoids (1 injection) with imaging used to evaluate efficacy - FDG-PET/CT Liposomal glucocorticoids Enhanced circulation half-life Protection from inactivation and interactions with plasma constituents Lobatto M et al. Molecular Pharmaceutics 2010 NP Free

28 Correlation with Histology Lobatto M et al. Molecular Pharmaceutics 2010 Willem J.M. Mulder

29 Statins have anti-inflammatory pleiotropic effects Statins are potent cholesterol-lowering drugs Anti-inflammatory effects are independent of their cholesterol-lowering capability Modulation of macrophages is a major contributor to anti-inflammatory effects HDL drug delivery

30 Statins have high liver uptake and low bioavailability to atherosclerotic macrophages Corsini et al. Pharmacol Therapeut 1999 HDL drug delivery

31 HDL is a natural nanoparticle HDL binds to macrophages via ABCA1, ABCG1 and SR-B1 receptors [S]-rHDL mimics natural HDL [S]-rHDL could be loaded with imaging labels HDL drug delivery Statin loaded rhdl nanoparticles ([S]-rHDL) target atherosclerotic macrophages

32 HDL drug delivery [S]-rHDL inhibits atherosclerosis progression N=32 (8 per group)

33 Aggressive [S]-rHDL nanotherapy induces plaque regression by depleting macrophages in plaques 4x for 1 week

34 NIH/NHLBI Program of Excellence in Nanotechnology (PEN)

35 MSSM Valentin Fuster Burton Drayer Michael Farkouh Jagat Narula Bachir Taouli Matthew Cham Willem Mulder David Cormode Venkatesh Mani Claudia Calcagno Wei Chen Torjus Skajaa June Tang Raphael Duivenvoorden Acknowledgements Funding American Heart Association fellowship (DPC) K99 EB (DPC) NHLBI R21 HL (KSB) NIH/NCRR S10RR02656 & S10RR (CYT) NIH R01 HL071021, HL and EB009638; NIH/NCRR UL1RR029887; NHLBI HHSN C (ZAF) NYU Edward Fisher Cambridge University James Rudd Ziad Mallat MGH Ahmed Tawakol UCSD Sam Tsimikas MIT Bob Langer AMC John J.P. Kastelein Eric Stroes WUSTL Gwen Randolph MSSM Pathology Lab (TEM) Ronald Gordon Heather Bell

Willem J.M. Mulder, Ph.D. Assistant Professor of Radiology Assistant Professor of Gene and Cell Medicine Director Nanomedicine Laboratory

Willem J.M. Mulder, Ph.D. Assistant Professor of Radiology Assistant Professor of Gene and Cell Medicine Director Nanomedicine Laboratory Willem J.M. Mulder, Ph.D. Assistant Professor of Radiology Assistant Professor of Gene and Cell Medicine Director Nanomedicine Laboratory Noordwijkerhout, The Netherlands 17-18 March 2011 Nanometer (10-9

More information

Molecular Imaging of Coronary Plaques

Molecular Imaging of Coronary Plaques Molecular Imaging of Coronary Plaques Daniel S. Berman, MD Director, Cardiac Imaging Cedars-Sinai Heart Institute CSMC 20113 Professor of Medicine David Geffen School of Medicine at UCLA Zahi A. Fayad,

More information

Expanding its HDL strategy into Immuno-oncology and Chemotherapeutic drug delivery. Acquisition of LYPRO Biosciences

Expanding its HDL strategy into Immuno-oncology and Chemotherapeutic drug delivery. Acquisition of LYPRO Biosciences Expanding its HDL strategy into Immuno-oncology and Chemotherapeutic drug delivery Acquisition of LYPRO Biosciences CERENIS is well positioned to change the drug delivery paradigm Over a decade of experience

More information

The Cardiovascular Institute Mount Sinai School of Medicine, New York

The Cardiovascular Institute Mount Sinai School of Medicine, New York The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine

More information

CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery

CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery Press release CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery Combining LYPRO Biosciences NanoDisk technology with CERENIS

More information

HARVARD MEDICAL SCHOOL

HARVARD MEDICAL SCHOOL The Role of the Various Monocyte Types in Atherothrombotic Disease Protective vs. Detrimental Effects and Therapeutic Implications Matthias Nahrendorf MGH Center for Systems Biology http://csb.mgh.harvard.edu/investigator/matthias_nahrendorf

More information

LDL How Low can (should) you Go and be Safe

LDL How Low can (should) you Go and be Safe LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and

More information

Lp(a) Ready for prime time? E Stroes AMC

Lp(a) Ready for prime time? E Stroes AMC Lp(a) Ready for prime time? E Stroes AMC Case Male, 45 years old Hypertension: DM: Smoking: Dyslipidemia: Fam history: brother MI (55yr) Lipoprotein(a): 1240 mg/l!!! Lipoprotein(a) = LDL + apo(a) tail

More information

National Lipid Association Keynote Address

National Lipid Association Keynote Address National Lipid Association Keynote Address The Regression of Atherosclerosis the journey from the liver to the plaque and back Edward A. Fisher, MD, PhD, MPH, FAHA Leon H. Charney Professor of Cardiovascular

More information

High density lipoprotein metabolism

High density lipoprotein metabolism High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

Summary and concluding remarks

Summary and concluding remarks Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated

More information

VasoRx: Atherosclerotic Plaque Regression

VasoRx: Atherosclerotic Plaque Regression VasoRx: Atherosclerotic Plaque Regression A progressive disease characterized by plaque build-up in large arteries, leading to heart attacks, stroke, and peripheral vascular disease. Induced by a combination

More information

2017 ANNUAL RESULTS AND UPDATE ON TANGO

2017 ANNUAL RESULTS AND UPDATE ON TANGO Press release 2017 ANNUAL RESULTS AND UPDATE ON TANGO Solid cash position of 16.3 million at December 31, 2017 TANGO timing update: results postponed, full 12 month results expected in Q4 2018 per protocol

More information

Treatment of Atherosclerosis in 2007

Treatment of Atherosclerosis in 2007 Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease

More information

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia The trial ClinicalTrials.gov number: NCT00552097 John J.P. Kastelein, MD, PhD* Department of Vascular Medicine Academic Medical Center

More information

Citation for published version (APA): van der Valk, F. M. (2016). Translating lipid-driven infammation in atherosclerosis

Citation for published version (APA): van der Valk, F. M. (2016). Translating lipid-driven infammation in atherosclerosis UvA-DARE (Digital Academic Repository) Translating lipid-driven infammation in atherosclerosis van der Valk, Fleur Link to publication Citation for published version (APA): van der Valk, F. M. (2016).

More information

Anne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA

Anne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,

More information

EAS Congress Innsbruck Highlights: A programme to excite, inspire and inform!

EAS Congress Innsbruck Highlights: A programme to excite, inspire and inform! Press release 84 th European Atherosclerosis Society Congress, Innsbruck, Austria For circulation 29 th May, 2016. 84 th Annual Congress of the European Atherosclerosis Society (EAS) May 29 th - June 1

More information

Nanobiologics Promotes Organ Transplant Acceptance

Nanobiologics Promotes Organ Transplant Acceptance Immunity, Volume 49 Supplemental Information Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance Mounia S. Braza, Mandy M.T. van Leent, Marnix Lameijer,

More information

A Statin-Loaded Reconstituted High-Density Lipoprotein Nanoparticle Inhibits Atherosclerotic Plaque Inflammation

A Statin-Loaded Reconstituted High-Density Lipoprotein Nanoparticle Inhibits Atherosclerotic Plaque Inflammation A Statin-Loaded Reconstituted High-Density Lipoprotein Nanoparticle Inhibits Atherosclerotic Plaque Inflammation The Harvard community has made this article openly available. Please share how this access

More information

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017 Coronary Artery Calcification Dharmendra A. Patel, MD MPH Director, Echocardiography Laboratory Associate Program Director Cardiovascular Disease Fellowship Program Erlanger Heart and Lung Institute UT

More information

Multi-Modality Imaging of Atherosclerosis in HIV Ahmed Tawakol, MD

Multi-Modality Imaging of Atherosclerosis in HIV Ahmed Tawakol, MD Multi-Modality Imaging of Atherosclerosis in HIV Ahmed Tawakol, MD Director, Integrative Bio-Imaging Trials Program Co-Director Cardiac MR PET CT Program Massachusetts General Hospital Harvard Medical

More information

PCSK9 Inhibitors and Modulators

PCSK9 Inhibitors and Modulators PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s

More information

Hybrid Lipid-Coated Silver Nanoparticles for Drug Delivery. Sven Burke and Marilyn R. Mackiewicz, Ph.D.

Hybrid Lipid-Coated Silver Nanoparticles for Drug Delivery. Sven Burke and Marilyn R. Mackiewicz, Ph.D. Hybrid Lipid-Coated Silver Nanoparticles for Drug Delivery. Sven Burke and Marilyn R. Mackiewicz, Ph.D. 1 What is the driving force behind our research? 2 Men Women Cancer is 2 nd deadliest disease in

More information

Nanodevices for Treatment of Hyperlipidemia

Nanodevices for Treatment of Hyperlipidemia Nanodevices for Treatment of Hyperlipidemia Vladimir Reukov, Daniel Carey and Alexey Vertegel Bioengineering Department, Clemson University, SC, USA Atherosclerosis is the leading cause of death in the

More information

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center

More information

C. Michael Wright, MD FACC DABCL_FNLA Biography March 2017

C. Michael Wright, MD FACC DABCL_FNLA Biography March 2017 C. Michael Wright, MD FACC DABCL_FNLA Biography March 2017 Address 13090 Caminito del Rocio Del Mar, CA 92014 Cell Phone 858-699-1958 Email cmichael.wright@gmail.com DEA FW3193113 California Medical License

More information

COURAGE to Leave Diseased Arteries Alone

COURAGE to Leave Diseased Arteries Alone COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist

More information

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools. UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

Pharmacological Modification of Biomarkers and CV Risk

Pharmacological Modification of Biomarkers and CV Risk Pharmacological Modification of Biomarkers and CV Risk Jin-Ok Jeong Cardiovascular Center Chungnam National University Hospital Cardiovascular Center, Chungnam National University Hospital 1 The Ideal

More information

Cholesterol; what are the future lipid targets?

Cholesterol; what are the future lipid targets? Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,

More information

Prof. John Chapman, MD, PhD, DSc

Prof. John Chapman, MD, PhD, DSc Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris

More information

TITLE: Control of Atherosclerosis Regression by PRMT2 in Diabetes

TITLE: Control of Atherosclerosis Regression by PRMT2 in Diabetes AWARD NUMBER: W81XWH-16-1-0374 TITLE: Control of Atherosclerosis Regression by PRMT2 in Diabetes PRINCIPAL INVESTIGATOR: Edward Fisher, MD, PhD CONTRACTING ORGANIZATION: New York University New York, NY

More information

NEW HORIZONS IN CARDIOVASCULAR MEDICINE

NEW HORIZONS IN CARDIOVASCULAR MEDICINE NEW HORIZONS IN CARDIOVASCULAR MEDICINE for the Primary Care Provider WEDNESDAY JANUARY 17, 2018 COURSE DIRECTORS Valentin Fuster, MD, PhD, MACC Samin K. Sharma, MD, FSCAI, FACC Icilma Fergus, MD, FACC

More information

Challenges and Opportunities for In Vivo Imaging in Oncology

Challenges and Opportunities for In Vivo Imaging in Oncology Challenges and Opportunities for In Vivo Imaging in Oncology Daniel C. Sullivan, M.D. Unraveling of the genome and proteome, and advances in biomedical technology are changing the practice of medicine

More information

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet? Evolving Role of Coronary CTA in Primary Cardiovascular Disease Prevention: Are We There Yet? Ron Blankstein, M.D., F.A.C.C. Co-Director, Cardiovascular Imaging Training Program Associate Physician, Preventive

More information

Distinguishing FH from non-fh: Right therapy, right patient, right time. Joshua W. Knowles, MD, PhD Stanford and the FH Foundation

Distinguishing FH from non-fh: Right therapy, right patient, right time. Joshua W. Knowles, MD, PhD Stanford and the FH Foundation Distinguishing FH from non-fh: Right therapy, right patient, right time Joshua W. Knowles, MD, PhD Stanford and the FH Foundation Disclosures Role as CMA of the FH Foundation is not compensated. www.thefhfoundation.org

More information

Prevalence and Risk Factors of Carotid Vessel Wall Inflammation in Coronary Artery Disease Patients

Prevalence and Risk Factors of Carotid Vessel Wall Inflammation in Coronary Artery Disease Patients JACC: CARDIOVASCULAR IMAGING VOL. 4, NO. 11, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36.00 PUBLISHED BY ELSEVIER INC. DOI:10.1016/j.jcmg.2011.07.008 Prevalence and Risk

More information

TREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal.

TREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal. TREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal. MISSION & VISION Our mission is to develop more effective strategies and safer products

More information

Sirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR

Sirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR Sirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR DR. SAMEER I DANI Director, Department of Cardiology, Apollo Hospital & Life Care Institute (LIMSAR), Ahmedabad, India. IN STENT RESTENOSIS

More information

Central role of apociii

Central role of apociii University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,

More information

ACC/AHA Guidelines Bulls-eyes and Misses

ACC/AHA Guidelines Bulls-eyes and Misses ACC/AHA Guidelines Bulls-eyes and Misses James Trippi, MD, FACC Diplomate American Board of Clinical Lipidology Complex Cholesterol Center of St. Vincent Health Indianapolis, IN October 18, 2014 Level

More information

Development of Multifunctional Nanoparticles for Brain Tumor Imaging and Therapy

Development of Multifunctional Nanoparticles for Brain Tumor Imaging and Therapy Development of Multifunctional Nanoparticles for Brain Tumor Imaging and Therapy Omid Veiseh, Ph.D. Professor Miqin Zhang s Nanomedicine and Biomaterials Lab Departments of Materials Science & Engineering

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

Familial Hypercholesterolemia

Familial Hypercholesterolemia Familial Hypercholesterolemia Dr.Ramzi Al-Mohammadi Assistant Professor of Medicine Interventional Cardiologist, Advanced HF and Transplant Consultant Classification of Hyperlipedemia Primary hyperlipedemia:

More information

Medpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development in lipid studies.

Medpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development in lipid studies. THE POWER OFx MEDPACE ADVANTAGE FOR LIPID STUDIES Experts. Experience. Execution. Medpace, a pioneer in the development of therapeutics to treat metabolic disorders, is your first stop for compound development

More information

Imaging Omics Behavior

Imaging Omics Behavior Scientific Bases of Health Subclinical Systemic Disease Imaging Omics Behavior ACC New York, Dec 8, 2017 No Disclosures From Aging / Disease to Youth / Health Primordial 00-25 yrs NHLBI $-1 Primary 25-50

More information

FFR-CT Not Ready for Primetime

FFR-CT Not Ready for Primetime FFR-CT Not Ready for Primetime Leslee J. Shaw, PhD, MASNC, FACC, FAHA, FSCCT R. Bruce Logue Professor of Medicine Co-Director, Emory Clinical CV Research Institute Emory University School of Medicine Atlanta,

More information

Novel Reduction of PCSK9 Expression: Mechanistic Insights into the Anti-Atherosclerotic & Hypolipidemic Effects of Heat Shock Protein 27

Novel Reduction of PCSK9 Expression: Mechanistic Insights into the Anti-Atherosclerotic & Hypolipidemic Effects of Heat Shock Protein 27 Novel Reduction of PCSK9 Expression: Mechanistic Insights into the Anti-Atherosclerotic & Hypolipidemic Effects of Heat Shock Protein 27 Ed O Brien, Jean-Claude Bakala-N Goma, Chunhua Shi Cumming School

More information

Cilostazol: Triple Benefits More is Better!

Cilostazol: Triple Benefits More is Better! Cilostazol: Triple Benefits More is Better! Matthew J. Price, MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute,

More information

Imaging of Coronary Atherosclerosis. Dr Marc Dweck BHFSenior Lecturer Edinburgh Heart Centre& University of Edinburgh

Imaging of Coronary Atherosclerosis. Dr Marc Dweck BHFSenior Lecturer Edinburgh Heart Centre& University of Edinburgh Imaging of Coronary Atherosclerosis Dr Marc Dweck BHFSenior Lecturer Edinburgh Heart Centre& University of Edinburgh Echo CT Angiography& Plaque MRI - Assess Anginal Symptoms SPECT PERFUSION - Risk Stratification

More information

Dysfunctional HDL and Coronary Artery Disease (CAD) UMHS-PUHSC JOINT INSTITUTE

Dysfunctional HDL and Coronary Artery Disease (CAD) UMHS-PUHSC JOINT INSTITUTE Dysfunctional HDL and Coronary Artery Disease (CAD) UMHS-PUHSC JOINT INSTITUTE PIs and Members of HDL Project Wei Gao, M.D., Ph.D. Professor and Chair Cardiology Third Hospital, PUHSC Yong Huo, M.D., Ph.D.

More information

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic

More information

Sunday, March 22, 2015

Sunday, March 22, 2015 SCIENTIFIC PROGRAMME (As of October 7, 2014) Sunday, March 22, 2015 12:00-13:30 Educational Symposium - Supported Session 12:00-13:30 Educational Symposium - Supported Session Hall B 13:30-14:00 Break

More information

Latest Guidelines for Lipid Management

Latest Guidelines for Lipid Management Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline

More information

March 30, 2014, Joint ACC/JAMA Late-breaking Clinical Trials Session 402 American College of Cardiology, Washington DC

March 30, 2014, Joint ACC/JAMA Late-breaking Clinical Trials Session 402 American College of Cardiology, Washington DC A Phase 3 Double-blind, Randomized Study to Assess Safety and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of Statin Erik Stroes 1, David Colquhoun

More information

Disclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values

Disclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values 39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives

More information

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry

More information

Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane

Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)

More information

CLINICAL CARDIOLOGY TOP TEN TOPICS IN FRIDAY, OCTOBER 5, Patient Focused Evidence-Based Approach

CLINICAL CARDIOLOGY TOP TEN TOPICS IN FRIDAY, OCTOBER 5, Patient Focused Evidence-Based Approach TOP TEN TOPICS IN CLINICAL CARDIOLOGY Patient Focused Evidence-Based Approach FRIDAY, OCTOBER 5, 2018 STERN AUDITORIUM Icahn School of Medicine at Mount Sinai 1468 Madison Avenue at 100th Street New York,

More information

New Frontiers in Atherosclerotic Disease and Myocardial Infarction: From local inflammation to systemic stem and progenitor cell reaction

New Frontiers in Atherosclerotic Disease and Myocardial Infarction: From local inflammation to systemic stem and progenitor cell reaction New Frontiers in Atherosclerotic Disease and Myocardial Infarction: From local inflammation to systemic stem and progenitor cell reaction Matthias Nahrendorf MGH Center for Systems Biology http://csb.mgh.harvard.edu/investigator/matthias_nahrendorf

More information

Cholesterol Reduction Therapy in 2018 A Perspective Role Of Statins, Ezetimibe and PCSK9-Inhibitors

Cholesterol Reduction Therapy in 2018 A Perspective Role Of Statins, Ezetimibe and PCSK9-Inhibitors USC-April 21, 2018, Los Angeles Cholesterol Reduction Therapy in 2018 A Perspective Role Of Statins, Ezetimibe and PCSK9-Inhibitors P.K.Shah, MD, MACC Shapell and Webb Chair in Clinical Cardiology, Director,

More information

Session: DEB their Utility. Innovation in Drug Coated Balloons

Session: DEB their Utility. Innovation in Drug Coated Balloons Session: DEB their Utility 2 nd MARCH 2014 Innovation in Drug Coated Balloons Dr. Upendra Kaul Fortis Escorts Heart Institute New Delhi Disclosure I, Upendra Kaul, do not have a financial interest/arrangement

More information

CardioHealth Station. powered by. Healthcare CardioHealth

CardioHealth Station. powered by. Healthcare CardioHealth CardioHealth Station FDA cleared, in-office ultrasound imaging that helps you directly identify atherosclerotic cardiovascular disease (ASCVD) allowing you to make a more informed decision about your patients

More information

ENHANCED NIR RADIATION-TRIGGERED HYPERTHERMIA BY MITOCHONDRIAL TARGETING

ENHANCED NIR RADIATION-TRIGGERED HYPERTHERMIA BY MITOCHONDRIAL TARGETING ENHANCED NIR RADIATION-TRIGGERED HYPERTHERMIA BY MITOCHONDRIAL TARGETING J. Am. Chem. Soc., 2015, 137, 3017-3023 Tanja Krainz Current Literature December 19, 2015 What is Hyperthermia? Hyperthermia (also

More information

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017 Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital

More information

Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia

Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia ORION-1 Trial Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia Lawrence A Leiter, MD, FRCPC, FACP, FACE, FAHA St Michael s Hospital, Toronto 1 Presented on behalf

More information

ZEUS Trial ezetimibe Ultrasound Study

ZEUS Trial ezetimibe Ultrasound Study Trial The lower, The better Is it True for Plaque Regression? Statin alone versus Combination of Ezetimibe and Statin Juntendo University, Department of Cardiology, Tokyo, Japan Katsumi Miyauchi, Naohisa

More information

The Vulnerable Plaque- Pharmacological Approaches

The Vulnerable Plaque- Pharmacological Approaches The Vulnerable Plaque- Pharmacological Approaches J. C. Kaski, M.D., D.M (Hons.), D.Sc., F.E.S.C., F.R.C.P., F.A.C.C., F.A.H.A. Cardiovascular and Cell Sciences Research Institute DISCLOSURES Speaker honoraria

More information

Lipid Lowering in Patients at High Risk for Cardiovascular Disease

Lipid Lowering in Patients at High Risk for Cardiovascular Disease Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel

More information

A Phase 3 Study of Lomitapide, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia

A Phase 3 Study of Lomitapide, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia A Phase 3 Study of Lomitapide, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia Marina Cuchel, MD, PhD University of Pennsylvania, Philadelphia,

More information

The aorta is an integral part of the cardiovascular system and should not be considered as just a conduit for blood supply from the heart to the

The aorta is an integral part of the cardiovascular system and should not be considered as just a conduit for blood supply from the heart to the The aorta is an integral part of the cardiovascular system and should not be considered as just a conduit for blood supply from the heart to the limbs and major organs. A range of important pathologies

More information

James Lu & Norman Mazer Clinical Pharmacology, F. Hoffman-La Roche

James Lu & Norman Mazer Clinical Pharmacology, F. Hoffman-La Roche Application of a mechanistic, systems model of lipoprotein metabolism and kinetics (LMK) to target selection and biomarker identification in the reverse cholesterol transport (RCT) pathway James Lu & Norman

More information

Perspectives on Large Simple Trials

Perspectives on Large Simple Trials Perspectives on Large Simple Trials Michael S Lauer, MD, FACC, FAHA Director, Division of Cardiovascular Sciences NHLBI/NIH May 8, 2012 Disclosures: None financial; my views only Three Questions Why trials?

More information

Glossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein

More information

Safety of Lipid-lowering Drugs Frank Ruschitzka, MD, FRCP Professor of Cardiology Head, Heart Failure/Transplantation University Clinic Zurich

Safety of Lipid-lowering Drugs Frank Ruschitzka, MD, FRCP Professor of Cardiology Head, Heart Failure/Transplantation University Clinic Zurich Safety of Lipid-lowering Drugs Frank Ruschitzka, MD, FRCP Professor of Cardiology Head, Heart Failure/Transplantation University Clinic Zurich Conflict of interest: Bayer, Biomarin, Biotronik, Cardiorentis,

More information

ESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE

ESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE ESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE Professor Željko Reiner, MD, PhD,FRCP(Lond), FESC Director, University Hospital Center Zagreb School of Medicine, University of Zagreb,

More information

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016 Is Universal Pediatric Lipid Screening Justified? YES Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016 None Disclosures What is a Pediatrician? Pediatrics is the specialty of medical science

More information

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice 2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine

More information

Coronary Artery Calcium. Vimal Ramjee, MD FACC The Chattanooga Heart Institute

Coronary Artery Calcium. Vimal Ramjee, MD FACC The Chattanooga Heart Institute Coronary Artery Calcium Vimal Ramjee, MD FACC The Chattanooga Heart Institute Disclosures I have no conflicts of interest to disclose. Objectives Recognize the utility of coronary artery calcium scoring

More information

Assessment Of Myocardial Viability

Assessment Of Myocardial Viability Assessment Of Myocardial Viability James K. Min, MD FACC President, Society of Cardiovascular Computed Tomography Associate Professor of Medicine, UCLA School of Medicine Associate Professor of Medicine

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

Update on inclisiran Discussion of ORION-1 trial

Update on inclisiran Discussion of ORION-1 trial Update on inclisiran Discussion of ORION-1 trial Conference call: March 17, 2017 4:30 pm 5:30 pm, EDT 1 Forward-looking statements Statements contained in this presentation that are not purely historical

More information

Innovation Interlude: Molecular Imaging in Cardiology. Celestial Doppelgangers and Relativity

Innovation Interlude: Molecular Imaging in Cardiology. Celestial Doppelgangers and Relativity Innovation Interlude: Molecular Imaging in Cardiology Jonathan R. Lindner, M.D. M. Lowell Edwards Professor of Cardiology Knight Cardiovascular Institute Oregon National Primate Research Center Oregon

More information

Cottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?

Cottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Cottrell Memorial Lecture Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Stephen Nicholls MBBS PhD @SAHMRI_Heart Disclosures Research support: AstraZeneca,

More information

Primary efficacy & safety outcomes

Primary efficacy & safety outcomes ORION-1 Primary efficacy & safety outcomes LDL-C reduction from 6 to 9 months following single or second injections of inclisiran, a novel sirna compound Kausik K Ray, Ulf Landmesser, Lawrence A Leiter,

More information

Primary efficacy & safety outcomes. LDL-C reduction from 6 to 9 months following single or second injections of inclisiran, a novel sirna compound

Primary efficacy & safety outcomes. LDL-C reduction from 6 to 9 months following single or second injections of inclisiran, a novel sirna compound ORION-1 Primary efficacy & safety outcomes LDL-C reduction from 6 to 9 months following single or second injections of inclisiran, a novel sirna compound Kausik K Ray, Ulf Landmesser, Lawrence A Leiter,

More information

The Evolving Science of Health Imaging, Genetics and Behavior. The Heart and the Brain

The Evolving Science of Health Imaging, Genetics and Behavior. The Heart and the Brain The Evolving Science of Health Imaging, Genetics and Behavior The Heart and the Brain Lima, Nov 17, 2018 No Disclosures From Aging / Disease to Youth / Health Primordial 00-25 yrs NHLBI $-1 Primary 25-50

More information

Η Πυρηνική Καρδιολογία Το 2017 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΑΠΕΙΚΟΝΙΣΤΙΚΩΝ ΤΕΧΝΙΚΩΝ

Η Πυρηνική Καρδιολογία Το 2017 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΑΠΕΙΚΟΝΙΣΤΙΚΩΝ ΤΕΧΝΙΚΩΝ Η Πυρηνική Καρδιολογία Το 2017 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΑΠΕΙΚΟΝΙΣΤΙΚΩΝ ΤΕΧΝΙΚΩΝ huma human n Setting diagnosis of the early stages of chronic diseases (i.e cancer, neuropsychiatric, cardiovascular disorders), in

More information

Can We Cure Atherosclerosis?

Can We Cure Atherosclerosis? Can We Cure Atherosclerosis? Jennifer G Robinson MD MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University of Iowa What if you had a guide To guarantee

More information

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical

More information

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:

More information

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

More information

N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP

N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP Omega or N-3 Fatty Acids (FA) significantly reduce TG synthesis and significantly deplete the TG content of VLDL particles indicated by significantly reduced V. FA are the substrate for TG synthesis. N3-FA

More information

Lipid/Lipoprotein Structure and Metabolism (Overview)

Lipid/Lipoprotein Structure and Metabolism (Overview) Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures

More information